Evidence map›Paper›PMID 40959261›Full record

ArticleACS medicinal chemistry letters2025

Discovery of Potent and Selective Quinoline-Based Toll-like Receptor 9 Antagonists.

Xue Song, Chen-Guo Feng, Chen Wang, Jay Cheng, Guo-Qiang Lin

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in ACS medicinal chemistry letters, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Xue SongResearch Center of Chiral Drug, Innovation Research Institute of Traditional Chinese Medicine, Shanghai University of Traditional Chinese Medicine, Shanghai 201203, P. R. China.
Chen-Guo FengResearch Center of Chiral Drug, Innovation Research Institute of Traditional Chinese Medicine, Shanghai University of Traditional Chinese Medicine, Shanghai 201203, P. R. China.ORCID https://orcid.org/0000-0001-9899-9489
Chen WangOtsuka Shanghai Research Institute, 919 Ziping Road, Shanghai 201321, P. R. China.
Jay ChengOtsuka Shanghai Research Institute, 919 Ziping Road, Shanghai 201321, P. R. China.ORCID https://orcid.org/0000-0002-5902-0490
Guo-Qiang LinResearch Center of Chiral Drug, Innovation Research Institute of Traditional Chinese Medicine, Shanghai University of Traditional Chinese Medicine, Shanghai 201203, P. R. China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The Toll-like receptor (TLR) family are critical components of the innate immune system, acting as pattern recognition receptors that detect microbial components and initiate immune responses. In humans, 10 TLRs have been identified, each recognizing distinct pathogen-associated molecular patterns. Among these, TLR9 is unique in its ability to sense CpG motifs, playing a crucial role in the detection of bacterial and viral DNA. Despite its significance, targeting TLR9 for therapeutics has proven to be challenging. Herein we describe the discovery of a series of potent and selective TLR9 antagonists, represented by 5-(hexahydropyrrolo-[3,4-

Indexed as

inflammationlupuspharmacodynamicpharmacokineticquinoline derivativesTLR7, TLR8, and TLR9 antagonists

Identifiers

PMID40959261
PMCPMC12434520

What Socratic holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.